Skip to Content


By Tami Luhby, quoting Rachel Sachs (Academic Fellow Alumna)
CNN
January 31, 2019

Read the Full Article

From the article:

"The Trump administration unveiled a proposal Thursday that could radically change the way many drugs are priced and paid for in Medicare and Medicaid.

The plan calls for effectively banning drug makers from providing rebates to pharmacy benefit managers and insurers in Medicare Part D- and Medicaid-managed care plans. Instead, drug companies would be encouraged to pass the discounts directly to patients at the pharmacy counter and would pay pharmacy benefit managers a fixed fee.
The move, which was immediately praised by pharmaceutical companies but panned by insurers and pharmacy benefit managers, would be one of the most substantial steps in the Trump administration's quest to lower drug prices.
"If this rule goes into effect in its current form, it would be the largest change the administration has yet announced on drug pricing," said Rachel Sachs, an associate law professor at Washington University."

Read more here!

Read the Full Article

Tags

health law policy   pharmaceuticals   rachel sachs   regulation